Introduction to Intravitreal Methotrexate

Each were treated with intravitreal methotrexate injections.

Three subsequent treatments with intravitreal methotrexate led to regression of the VRL.

To assess the effects of weekly post-operative intravitreal methotrexate injections on eyes with grade C proliferative vitreoretinopathy (PVR) that underwent surgical repair.

Optimal treatment for PVRL is not defined given its relatively low incidence but often requires a combination of systemic and/or intravitreal methotrexate and rituximab.

BACKGROUND/PURPOSE To investigate the clinical characteristics of intraocular lymphoma and to evaluate two protocols of intravitreal methotrexate injection.

Objective The objective of this pilot study was to evaluate the efficacy and safety of per-operative intravitreal methotrexate (MTX) infusion during vitrectomy in patients of retinal detachment (RD) with advanced grade proliferative vitreoretinopathy (PVR).

Patients received local and systemic therapies: intravitreal methotrexate (MTX, 400 μg, 0.

He was treated with multiple injections of intravitreal Methotrexate 400µg/0.

Herein we present anterior segment optical coherence tomography findings in a 21-years-old, male, diffuse B-cell Acute Lymphoblastic Leukemia (ALL) patient who has a leukemic iris infiltration in his left eye that was successfully treated with intravitreal methotrexate.

PURPOSE The purpose of this study was to evaluate the corneal toxicity of intravitreal methotrexate used for the prevention of proliferative vitreoretinopathy (PVR).

He sustained complete right vision loss due to right optic nerve invasion by the tumor, leading to prophylactic intravitreal methotrexate to the contralateral eye.

The patient was treated with intravitreal methotrexate with initial success, but eventual failure after 10 months.

The patient received intravitreal methotrexate 400 μg/0.

A subsequent relapse occurred that responded rapidly to intravitreal methotrexate in the absence of antiviral/antibiotics.

The patient was treated with pars plana vitrectomy as well as systemic chemotherapy, intrathecal methotrexate, intravitreal methotrexate, and intravitreal rituximab with good post-operative outcomes.

Additionally, the left eye received intravitreal methotrexate (MTX) (weekly for the first month, every two weeks for the second month, and monthly thereafter) over a course of twelve months.

Materials and methods A retrospective review was performed on a cohort of five consecutive eyes with severe PVR and recurrent retinal detachment that were treated with relaxing retinectomy, extended perfluorocarbon liquid tamponade (4–5 weeks) and a series of intravitreal methotrexate (MTX) injections (100–200 µg/0.

ABSTRACT Purpose To present a case of necrotizing retinitis with Epstein–Barr virus (EBV)-positive ocular fluid in a patient with sudden unilateral vision loss, which was successfully treated with intravitreal methotrexate (MTX) injections.

Results: The patient was treated with serial intravitreal methotrexate injections and subsequently developed a BRAO immediately following her seventh injection.